vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $56.6667.

A number of research firms have recently weighed in on VTVT. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Zacks Research downgraded shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings upgraded shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Finally, BTIG Research upped their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, July 16th.

Hedge Funds Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VTVT. Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the fourth quarter valued at approximately $731,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the fourth quarter valued at approximately $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Stock Down 0.0%

Shares of VTVT stock opened at $31.66 on Friday. The business has a fifty day simple moving average of $33.89 and a 200 day simple moving average of $35.26. The company has a market cap of $124.74 million, a P/E ratio of -34.04 and a beta of 0.25. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million. As a group, equities research analysts anticipate that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.